Characteristic | Melanoma | NSCLC | ||||||
Clinical benefit of prior anti-PD-1/PD-L1 therapy | All (N=16) | Clinical benefit of prior anti-PD-1/PD-L1 therapy | All (N=17) | |||||
Best overall response, n (%) | DCB (N=6) | NDCB (N=10) | Unknown (N=0) | DCB (N=7) | NDCB (N=9) | Unknown (N=1) | ||
Stable disease (SD) | 2 (33.3) | 1 (10.0) | – | 3 (18.8) | 3 (42.9) | 2 (22.2) | 1 (100.0) | 6 (35.3) |
Progressive disease (PD) | 4 (66.7) | 8 (80.0) | – | 12 (75.0) | 3 (42.9) | 2 (22.2) | 0 | 5 (29.4) |
Unknown | 0 | 1 (10) | – | 1 (6.3) | 1 (14.3) | 5 (55.6) | 0 | 6 (35.3) |
Overall response rate, %* | 0 | 0 | – | 0 | 0 | 0 | 0 | 0 |
Disease control rate, % (90% CI)† | 33.3 (6.3 to 72.9) | 10.0 (0.5 to 39.4) | – | 18.8 (5.3 to 41.7) | 42.9 (12.9 to 77.5) | 22.2 (4.1 to 55.0) | 100.0 (5.0 to 100.0) | 35.3 (16.6 to 58.0) |
*CR or PR.
†CR or PR or SD or NCRNPD.
CR, complete response; DCB, durable clinical benefit; NCRNPD, neither CR nor PD; NDCB, non-DCB; NSCLC, non-small cell lung cancer; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; PR, partial response; RECIST, Response Evaluation Criteria In Solid Tumours.